Evidence map›Paper›PMID 34973601›Full record

ArticlePsychiatry research. Neuroimaging2022

Racemic ketamine treatment attenuates anterior cingulate cortex GABA deficits among remitters in treatment-resistant depression: A pilot study.

Balwinder Singh, John D Port, Vanessa Pazdernik, Brandon J Coombes, Jennifer L Vande Voort, Mark A Frye

2 registry-linked trialsAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Psychiatry research. Neuroimaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03573349 early_phase1active not recruitingnot on this map

Central Versus Peripheral GABA and Glutamate Biomarkers for Treatment Response During Two Infusions of Intravenous Ketamine for Treatment-Resistant Depression

TypeinterventionalSponsorMayo ClinicRan2019 to 2026Enrolled18ConditionsMajor Depressive Disorder, Treatment Resistant Depression, Bipolar DepressionArmsKetamine
NCT06668571 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

Central and Peripheral GABA and Glutamate Modulation With Intravenous Ketamine for Treatment-Resistant Depression (G2K): A Randomized, Double-Blind, Placebo-Controlled Study

TypeinterventionalSponsorMayo ClinicRan2025 to 2027Enrolled30ConditionsDepressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD)ArmsKetamine, Normal Saline
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Modulation of GABA and glutamate by ketamine in depression: A systematic review and meta-analysis of magnetic resonance spectroscopy studies.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  3. Metabolomic correlates of intravenous racemic ketamine in treatment-resistant major depressive disorder: the Bio-K/NNDC multicenter trial.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry · 2026
    Article
  4. Negative allosteric modulation of α5-GABAbioRxiv : the preprint server for biology · 2026
    Article
  5. Effects of ketamine on GABAergic and glutamatergic activity in the mPFC: biphasic recruitment of GABA function in antidepressant-like responses.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Article
  6. Article
  7. Article
  8. M1 acetylcholine receptors in somatostatin interneurons contribute to GABAergic and glutamatergic plasticity in the mPFC and antidepressant-like responses.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Balwinder SinghDepartment of Psychiatry and Psychology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905 USA. Electronic address: singh.balwinder@mayo.edu.
John D PortDepartment of Psychiatry and Psychology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905 USA; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Vanessa PazdernikDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Brandon J CoombesDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Jennifer L Vande VoortDepartment of Psychiatry and Psychology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905 USA.
Mark A FryeDepartment of Psychiatry and Psychology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905 USA.

Funding

Mayo Clinic Center for Clinical and Translational Science (CCaTS UL1 Supplement - Dr. Timothy Curry)UL1TR002377 · NCATS · MAYO CLINIC ROCHESTER · PI VESNA D GAROVIC · 2017 to 2026
$78.4M
NCATS NIH HHS UL1 TR002377
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

KetamineDepressiongamma-Aminobutyric AcidGyrus CinguliHumansPilot Projectsgamma-Aminobutyric AcidKetamine

Identifiers

PMID34973601
PMCPMC11467890

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.